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Abstract The glycine transporter-1 inhibitor Org25935 is
a promising candidate in a treatment concept for alcohol
use disorder targeting the glycine system. Org25935 inhi-
bits ethanol-induced dopamine elevation in brain reward
regions and reduces ethanol intake in Wistar rats. This
study aimed to further characterise the compound and used
ethanol consumption, behavioral measures, and gene
expression as parameters to investigate the effects in
Wistar rats and, as pharmacogenetic comparison, Alko-
Alcohol (AA) rats. Animals were provided limited access
to ethanol in a two-bottle free-choice paradigm with daily
drug administration. Acute effects of Org25935 were esti-
mated using locomotor activity and neurobehavioral status.
Effects on gene expression in Wistar rats were measured
with qPCR. The higher but not the lower dose of Org25935
reduced alcohol intake in Wistar rats. Unexpectedly,
Org25935 reduced both ethanol and water intake and
induced strong CNS-depressive effects in AA-rats (with-
drawn from further studies). Neurobehavioral effects by
Org25935 differed between the strains (AA-rats towards
sedation). Org25935 did not affect gene expression at the
mRNA level in the glycine system of Wistar rats. The data
indicate a small therapeutic range for the anti-alcohol
properties of Org25935, a finding that may guide further
evaluations of the clinical utility of GlyT-1 inhibitors. The
results point to the importance of pharmacogenetic con-
siderations when developing drugs for alcohol-related
medical concerns. Despite the lack of successful clinical
outcomes, to date, the heterogeneity of drug action of
Org25935 and similar agents and the unmet medical need
justify further studies of glycinergic compounds in alcohol
use disorder.
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Abbreviations
AA Alko Alkohol rats
ANA Alko non-alcohol rats
AUD Alcohol use disorder
nAc Nucleus accumbens
GABA Gamma aminobutyric acid
NMDAR N-methyl-D-aspartate receptors
GlyR Glycine receptor
GlyT-1 Glycine transporter protein 1
Introduction
Alcohol use disorder (AUD) is a heterogeneous disorder
affecting multiple neurotransmitter systems of which the
mesolimbic dopamine system, a part of the reward path-
way, still attracts considerable interest. The reward signal
induced by alcohol (ethanol), as well as other drugs of
abuse, corresponds to a dopamine increase in nucleus
accumbens (nAc) (Di Chiara and Imperato 1988; Koob and
Bloom 1988; Wise 1996). Over time, chronic ethanol
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exposure may lead to neuroadaptations in the striatal
dopamine systems, which most likely contribute to the
development of addiction (Volkow et al. 2007; Koob and
Volkow 2010).
The search for improved pharmacotherapy with novel
mechanisms of action is an ongoing quest (Heilig and Egli
2006; Lim et al. 2013). One treatment concept under
investigation for AUD targets the glycinergic system.
Glycine serves dual functions with regards to neurotrans-
mission, as an agonist at inhibitory glycine receptors
(GlyRs) and as co-agonist at excitatory N-methyl-D-aspar-
tate receptors (NMDARs) (Bowery and Smart 2006; Kirsch
2006). Since both receptor populations are primary targets
for alcohol (Yevenes et al. 2008) and can modulate the
mesolimbic dopamine system, glycine-based compounds
may exert its action by a bimodal mechanism interacting
with GlyRs and NMDARs (Molander and So¨derpalm
2005a; Spanagel 20112009). The biological rationale for
glycine signaling as a therapeutic target for AUD originates
from animal models demonstrating that GlyRs in the nAc
are access points for ethanol to the mesolimbic dopamine
system (Soderpalm et al. 2009; Soderpalm and Ericson
2013). Glycine was shown to elevate extracellular dopa-
mine levels in the nAc and decrease ethanol consumption
in rats, and conversely, the GlyR antagonist strychnine was
found to decrease dopamine in the nAc and increase
ethanol consumption (Molander et al. 2005).
The glycine transporter 1 protein (GlyT-1) is the prin-
cipal regulator of extracellular glycine (Gomeza et al.
2003; Cubelos et al. 2005) and CNS glycine concentrations
are elevated by GlyT-1 inhibitors (Betz et al. 2006; Zafra
and Gimenez 2008). Several GlyT-1 inhibitors, initially
developed for the treatment of schizophrenia, have been
investigated with respect to interference with ethanol-in-
duced dopamine elevation as well as consumption. The
strongest GlyT-1 inhibitor candidate so far has been
Org25935, also known as SCH 900435 (Harvey and Yee
2013). Org25935 (chemical name: cis-N-methyl-N-(6-
methoxy-1-phenyl-1,2,3,4-tetrahydronaphthalen-2-yl-
methyl)amino-methylcarboxylic acid; Fig. 1) is a
sarcosine-based, non-competitive, and highly selective
GlyT-1 inhibitor lacking significant affinity for other
transporters and receptors, including those for dopamine,
serotonin, noradrenaline, glutamate, and gamma-
aminobutyric acid (GABA). Org25935 demonstrates
moderate potency (IC50 is 0.162 lmol/L) and high radi-
oligand binding in several brain regions in the rat (Andrews
et al. 2007). The compound shows dose-linear pharma-
cokinetics with dose-dependent selective increase of gly-
cine levels in frontal cortex (Andrews et al. 2007), nAc,
and dorsal striatum (Ge et al. 2001). Org25935 was also
demonstrated to induce a robust and long-lasting reduction
of voluntary ethanol consumption and reverse compulsive
relapse-like alcohol-drinking (Molander et al. 2007; Ven-
geliene et al. 2010). In more detail, administration of
Org25936 (6 mg/kg i.p.) evoked an 87% increase of
accumbal glycine levels, which, in turn, prevented ethanol
from increasing dopamine in the same brain region (Lido¨
et al. 2009, 2011). These combined effects are believed to
underlie Org25935’s therapeutic potential.
The aim of this study was to further characterise
Org25935 with respect to neurobehavioral, anti-alcohol,
and gene expression effects. Current models of assessing
AUD have shown varying predictive validity, and for that
reason, it was of interest to add a pharmacogenetic aspect
in the evaluation of Org25935 (Egli 2005). Therefore, drug
responses were evaluated in Alko-Alcohol (AA) rats, a
genetic model for high alcohol preference, in addition to
outbred Wistar rats. The AA rat line demonstrates a tenfold
higher alcohol consumption compared to its counterpart,
the Alko Non-Alcohol (ANA) rat line (Eriksson 1968;
Sommer et al. 2006), yet the underlying genetic factors in
predilection towards ethanol drinking are not fully under-
stood (Hyytia et al. 1999; Ojanen et al. 2006). First, effects
of single doses of Org25935 on locomotor activity and
additional 10 neurobehavioral responses were evaluated.
Then, effects of repeated dosing of Org25935 were tested
in an ethanol consumption paradigm.
Another aim was to determine whether GlyT-1 inhibi-
tion would affect regional gene expression related to this
treatment. GlyRs are pentameric chloride-conducting
channels composed of a1-4 and b subunits, either as 2a3b-
heteromers or a-homomers (Grudzinska et al. 2005). Here,
expression of genes encoding GlyR subunits a1-3 (Glra1-
3) and b (Glrb) and transporters for glycine, i.e., GlyT-1
(Slc6a9) and taurine, TauT, (Slc6a6) were compared
between Org25935-treated animals and controls. Effects of
Org25935 on glycinergic gene expression have previously
been investigated, but only in caudate putamen and in
combination with ethanol consumption (Vengeliene et al.
2010). In a wider perspective, effects on amino-acid neu-
rotransmitters by glycine could affect inhibitory signaling
in general, making adjustments in the GABAergic system a
Fig. 1 Chemical structure of Org25935. For biochemical properties,
see ‘‘Introduction’’ section
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possible outcome of Org25935-treatment. Therefore, we
included genes for GABA transporters (GAT) 1 (Slc6a1)
and 3 (Slc6a11) and gephyrin (Gphn), the latter a protein
anchoring both GlyRs and GABAARs to the synapse. Gene
expression was monitored in regions involved in reward-
related behaviors, i.e., the nAc (also known as ventral
striatum), dorsal striatum, prefrontal cortex, and amygdala.
Materials and methods
Animals
A total of 80 male Wistar rats were supplied by Taconic
(Ejeby, Denmark), whereof 60 for the ethanol consumption
study (43 were selected after screening) and 20 for
behavioral assessment. Forty AA-rats were kindly provided
by Dr Petri Hyytia¨ (University of Helsinki, Finland), and
were used in the ethanol consumption study, whereof 20
were assessed in the behavioral battery. Animals were kept
under reversed light–dark conditions (lights off at 7.00 a.m.
and on at 7.00 p.m.) at constant room temperature (22 C)
and humidity (65%) with free access to water and standard
rat feed (Harlan Teklad Europe, UK). Rats weighed
300–400 g at the beginning of the experiment.
Drugs
Org25935 (provided by Organon Labs. Ltd., Newhouse,
UK, now merged with Merck, Sharp and Dohme, New-
house, Lanarkshire, UK), was dissolved in 0.9% NaCl and
administered i.p. at a volume of 2 ml/kg. The same volume
of 0.9% NaCl was used as vehicle. The dose of 6 mg/kg
Org25935 was selected based on the previous studies (Ge
et al. 2001; Molander et al. 2007; Lido¨ et al. 2009). The
compound was injected 40 min before the test sessions, as
extracellular glycine levels are expected to peak 50 min
after Org25935 administration (filed data, Organon Labs.
Ltd.). In the ethanol consumption study, a 2.5 h fluid
consumption period was chosen, since Org25935 increases
striatal glycine levels for 2.5 h (Ge et al. 2001). Two
300 mL drinking bottles were available during the drinking
session, one with regular tap water and one with ethanol
(Kemetyl AB, Haninge, Sweden). The animals were ran-
domly assigned to drug and vehicle groups in all
experiments.
Screening for ethanol preference
During 2 weeks of continuous access to ethanol and water,
the ethanol concentration was gradually increased from 2
to 6% for Wistar rats and from 2 to 10% for AA-rats. The
6% ethanol (v/v) solution was used for Wistar rats, since
ethanol consumption in this strain is highest at this con-
centration (Fahlke et al. 1994). A 10% ethanol (v/v) solu-
tion was used for AA-rats, since they are selectively bred
based on preference for a 10% solution (Eriksson 1968).
Animals were individually housed in plastic cages and fluid
intake was measured twice a week over a 5-week period.
The amount of ethanol solution consumed in percent of
total fluid intake was used as ethanol preference index.
Rats with[30% were included in the study (71% of Wistar
rats reached this criterion, 100% of AA-rats).
Behavioral activity: limited access drinking
experimental procedure
After the initial screening, the animals were placed on a
limited access paradigm. During the first week, rats had
access to ethanol and water for 2.5 h/day to adapt the
animals to the procedure and to establish a baseline limited
access drinking prior to the experiment. Rats were subse-
quently treated with daily Org25935 or NaCl, injected i.p.
40 min before being presented with the choice of ethanol
or water (drinking sessions lasted from 10.00 a.m. to
12.30 p.m.). Org25935 at doses of 3 or 6 mg/kg were
tested in two distinct sets of Wistar rats. Due to decreased
tolerance to the high dose of Org25935 in AA-rats, the dose
was lowered to 3 mg/kg 2 days into the experiment.
Behavioral activity: locomotor activity procedure
The locomotor apparatus consisted of eight sound-attenu-
ated, ventilated, and dimly lit monitoring boxes
(700 9 700 9 350 mm). For photocell detection, the
boxes were equipped with two levels of five by five rows of
photocell beams, placed 10 and 130 mm above the floor
level, respectively, and connected to a computer-based
system to register the activity of the rats (Kungsbacka ma¨t-
och reglerteknik AB, Fja¨ra˚s, Sweden). Locomotor activity
was defined as the accumulated number of new photocell
beams interrupted during a 30-min period. Rearing activity
was defined as the number of new photocell beams inter-
rupted at the top row of photocells.
Behavioral activity: the functional observational
battery
Neurobehavioral functioning was assessed using selected
measures from a previously described functional observa-
tional battery (Mattson et al. 1996). The measures were
selected based on behavioral observations following
administration of Org25935 in the previous experiments.
The battery consisted of ten behavioral, neurological, and
autonomic measures and rats were tested in the order listed:
overall status, respiration, aggressiveness, posture, muscle
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tone, catalepsy, righting response, rigidity, vocalisation,
and piloerection. The criteria for scoring were based on a
previous procedure for validation of behavioral activity
using categorical scorings (Ingman et al. 2004), and test
measures were evaluated by the rank score system (0–2) in
Table 1. Animals were assessed six times; 40, 50, 60, 70,
80, and 90 min after receiving Org25935 (6 mg/kg) or
NaCl i.p. At each test session, rats were evaluated inde-
pendently by two operators both blinded to the treatment,
and were returned to their home cages between sessions.
Gene expression: experimental design
Due to the deviant behavior observed following Org25935
challenge, AA-rats did not continue to gene expression
analysis, whereas Wistar rats underwent such an analysis,
with the aim to explore possible mechanisms underlying
the rapid adaptation to the initial CNS-depressive effect
(reduced water intake treatment day one and two). Twelve
adult male Wistar rats were used for this study. Rats
(180–200 g at arrival) were randomly assigned to active
treatment (Org25935, n = 6) or placebo (NaCl, n = 6) and
received daily administration (10.00 a.m.) for 19 consec-
utive days. No signs of intolerability were observed during
the treatment. On day 20, animals were decapitated and
brains dissected according to Heffner, using a brain matrix
and under strictly RNase-free conditions (Heffner et al.
1980). Brains were kept cold during dissection and dis-
sected tissues were collected in RNase-free Eppendorf
tubes, frozen on dry ice, and then kept at -80 C until
further processing.
RNA extraction and cDNA synthesis
RNA extraction and cDNA synthesis were performed as
previously described (Jonsson et al. 2009, 2012). Briefly,
samples were homogenised in 1-ml QIAzol Lysis Reagent
(Qiagen AB, Sollentuna, Sweden) and RNA was extracted
using a Qiagen RNeasy kit according to the manufacturer’s
protocol (Qiagen). RNA concentrations of all samples were
determined with a SmartSpec Plus spectrophotometer (Bio-
Rad Laboratories AB, Sweden) and material corresponding
to 1-lg RNA was used for cDNA synthesis (QuantiTect
Reverse Transcription Kit, Qiagen). Synthesis of cDNA
was performed in accordance with the manufacturer’s
instructions.
Real-time quantitative PCR analysis
QuantiTect Primer Assays were used for gene-specific
analysis (Qiagen), as previously described (Jonsson et al.
2009). Analyses of expression of reference genes (b-actin,
Table 1 Functional operational
battery: assessments and criteria
for scoring
Overall status Rigidity
0 Normal healthy rat 0 Normal
1 Mild deviation from normal status 1 Mild
2 Severe deviation from normal status 2 Severe
Neurologic signs Behavioral signs
Posture (curved back score) Aggressiveness
0 Normal 0 None
1 Mild curved back 1 Struggling when handled on a bench
2 Marked curved back 2 Struggling, must be kept in neck grip
Muscle tone Vocalisation
0 Normal 0 None
1 Somewhat flaccid 1 Some
2 Completely flaccid 2 Marked
Catalepsy Autonomic signs
0 Forelimb quickly removed from object Respiration
1 Delayed removal 0 Normal
2 Forelimb remains on object 1 Irregular/dyspnea
Righting response 2 Pronounced dyspnea or wheezing
0 Quick turn (to all paws under body) Piloerection
1 Slow turn 0 None
2 No turn 1 Mild
2 Marked
The ten behavioral, neurological, and autonomic measures recorded and the scoring criteria for scores of 0,
1, or 2 are presented. For further description, see ‘‘Materials and methods’’
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GAPDH, and RPL19) and target genes Glra1, Glra2, Glra3,
Glrb, Slc6a9, Slc6a6, Gphn, Slc6a1, and Slc6a11 were
carried out in 96-well plates using a LightCycler 480
Real-Time PCR System (Roche Applied Science). Cali-
brators and negative controls (in duplicates) were included
in every assay. Primer efficiencies were decided by stan-
dard curves with reverse-transcribed RNA. A melting
curve analysis for each sample was performed to ensure
that a single product was obtained. The threshold value,
(Ct), for each sample was determined by the LC 480
Software Version 1.5 (Roche Applied Science) and data
were exported as text files and imported into Microsoft
Excel for further statistical analyses. Normalisation and
analyses were performed as previously described (Pfaffl
2001; Jonsson et al. 2009).
Statistics
Data with continuous variables were statistically analyzed
using the analysis of variance (ANOVA) with repeated
measures in SPSS (version 17.0 for Windows). Analyses
revealing significant main effect or interactions were fol-
lowed by Fisher’s protected least significant-difference
(PLSD) test, paired t test within groups, or unpaired t tests
between groups, as appropriate. The behavioral data with
categorized ratings were evaluated by ordinal regression of
summary statistics using Proc Logistic (the logistic pro-
cedure) in Statistical Analysis System (SAS). Analysis of
gene expression was performed using Mann–Whitney tests
in SPSS. Grubbs test was used to exclude outliers
(GraphPad Software Inc., USA). The ethanol consumption
studies using Wistar and AA-rats differed in time and
experimental setups and these data sets were accordingly
analyzed separately. Results are presented as mean ± s-
tandard error of the mean (SEM) and a probability level
(p) of less than 0.05 was considered significant.
Results
Wistar rats—Effects of 6 mg/kg Org25935
on ethanol and water intake
Treatment with Org25935 for 5 days reduced ethanol intake
in comparison with the vehicle-treated group ANOVA over
day 1–8 (Fig. 2a) showed a significant effect of treatment
[F(1,21) = 5.223, p = 0.033], time [F(7,147) = 6.542,
p\ 0.001] and a treatment 9 time interaction
[F(7,147 = 7.409, p\ 0.001]. The anti-alcohol intake effect
was evident from the first day of treatment (p = 0.022).
Org25935 was also found to have initial effect on the water
intake (Fig. 2b) but no statistical effect over the whole treat-
ment period. ANOVA over day 1–8 showed effect of
treatment 9 time [interaction term: F(7,147) = 3.092,
p = 0.005] but no effect of group [F(1,21) = 0.510,
p = 0.483] or time [F(7,147) = 1.211, p = 0.300].
Wistar rats: effects of 3 mg/kg Org25935 on ethanol
and water intake
Treatment with Org25935 for 5 days did not influence
ethanol intake (treatment [F(1,20) = 1.000, p = 0.329],
time [F(8,160) = 0.998, p = 0.439], treatment 9 time
[F(8,160) = 0.997, p = 0.441]) or water intake (treatment
[F(8,17) = 0.106, p = 0.748], time [F(8,152) = 1.014,
p = 0.428], and treatment 9 time [F(8,152) = 1.603,
p = 0.129]) when analyzed by ANOVA over day 1–8
(Fig. 2c, d).
AA-rats: effects of 6 and 3 mg/kg Org25935
on ethanol and water intake
The effect of Org25935 on ethanol intake, dosed at 6 mg/kg
for 2 days followed by 3 mg/kg i.p for 6 days, is displayed in
Fig. 3a. Due to observed side-effects 2 days into the 6 mg/kg
challenge, treatment was discontinued in two rats, while one
rat was killed due to intolerable suffering and the dose was
lowered in the remaining rats. ANOVA over days 4–5
revealed an effect on group [F(1,36) = 8.811, p = 0.005] but
not time [F(1,36) = 0.020, p = 0.888] or interaction
[F(1,36) = 0.922, p = 0.343] during the 2 days of 6 mg/kg
challenge (Fig. 2a). There was a group effect
[F(1,36) = 7.071, p = 0.012] during the first 2 days of 3 mg/
kg (day 6 and 7 in Fig. 2a) but no time effect
[F(1,35) = 0.186, p = 0.669] or interaction term effect
[F(1,35) = 2.302, p = 0.138]. Ethanol intake was signifi-
cantly reduced compared to mean baseline level on day 4
(p = 0.002) and day 5 (p = 0.002) but returned to baseline
levels on day 6.Analysis ofwater intake revealed a significant
effect of time [F(10,290) = 2.306, p = 0.013] and interac-
tion [F(10,290) = 5.130, p\0.001] but not group
[F(1,29) = 3.564, p = 0.069] over the whole time period.
Over day 4 and 5, (see Fig. 3b) ANOVA revealed an effect of
6 mg/kg on water intake [F(1,34) = 24.753, p\ 0.001] but
no effects of time [F(1,34) = 1.301,p = 0.262] or interaction
[F(1,34) = 2.281, p = 0.140]. A difference between treated
animals and controlswas alsoobservedonday6 and7, thefirst
2 days of the 3 mg/kg dose regimen [F(1,32) = 13.439,
p = 0.001], time [F(1,32) = 4.612, p = 0.039], and inter-
action term [F(1,32) = 27.049, p\ 0.001].
Motor activity
Wistar rats displayed a higher baseline motor activity as
compared to AA-rats and Org25935 significantly reduced
motor activity in both strains, yet there were no treatment-
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related differences in motor activity between the strains.
Acute Org25935 suppressed locomotor (Fig. 4a, b) and
rearing activity (Fig. 4b, c) in both strains. A pattern of
habituation with an initially high motor activity, which
declined under the test session, was evident in both strains.
ANOVA revealed an overall effect of treatment
[F(1,36) = 25.252, p\ 0.001] and strain
[F(1,36) = 28.653, p\ 0.001] on locomotor activity, but
treatment effects did not differ between strains
[F(1,36) = 0.736, p = 0.397]. Similarly, for rearing
activity, an overall effect of treatment [F(1,36) = 46.603,
p\ 0.001] and strain [F(1,36) = 18.609, p\ 0.001] was
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observed, but no difference of treatment between strains
[F(1,36) = 0.269, p = 0.607].
Behavioral and neurological measures
The scoring criteria for scores of 0, 1, or 2 are presented in
Table 1. The maximum group score possible per session
was 20 (n = 10/group). Each rat was evaluated at six time-
points, at 40, 50, 60, 70, 80, and 90 min after drug
administration (time wise scores are not shown). The total
group scores and number of scoring rats per group are
presented in Table 2, where asterisk indicates significant
p values. Overall status: A score was given if behavior or
status differed from healthy naı¨ve rats. Ordinal regression
revealed a significant effect of treatment (p\ 0.001), but
not of ratline or interaction treatment 9 ratline. Respira-
tion: No significant differences in respiration were found.
Two AA-rats receiving Org25935 demonstrated dyspnoea
and wheezing symptoms after 60 min. Aggressiveness: A
trend towards effect of ratline (p = 0.080) but not for
treatment or interaction treatment 9 ratline (p = 0.452)
was found. Four Org25935-treated Wistars, as compared to
one rat in other treatment groups, displayed aggressive
behavior. Body posture: The body posture was measured
based on the curvature of the back and effect of treatment
was manifested in both strains (p\ 0.001) but not of rat-
line or interaction treatment 9 ratline. None of the mea-
sures muscle tone, catalepsy, righting response, muscle
tone, stiffness, vocalisation, or piloerection displayed any
differences.
To further analyze differences in treatment response
between the strains, Wistar rats and AA-rats were analyzed
separately. For overall status and body posture, a signifi-
cant treatment effect was observed in both AA-rats
(p\ 0.001) and Wistars (p\ 0.001). There was a trend
towards treatment effect on righting response in AA-rats
(p = 0.0865) but not in Wistars (p = 0.9374). Org25935
increased vocalisation in Wistar (p = 0.032) but not in
AA-rats. Trends towards an effect of Org25935 treatment
in AA-rats on muscle tone and righting response were
observed. The total score for muscle tone was 41 in AA
versus 10 in Wistar rats, whereas total score for righting
response was 39 in AA versus 3 in Wistar rats receiving
Org25935.
Gene expression
Mann–Whitney tests used to compare the relative gene
expression between Org25935-treated Wistar rats and
controls revealed only two significant differences in gene
expression, both in the amygdala (Fig. 5). In this region,
Org25935-treatment resulted in up-regulation of Slc6a6
(TauT, p = 0.004) and down-regulation of Slc6a1 (GAT-1,
p = 0.009). A trend towards down-regulation was also
observed in Slc6a11 expression (GAT-3, p = 0.065).
Another trend, also towards down-regulation in Org25935-
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counts during the entire 30-min
period (a) and as effect over
time, where counts every 5 min
were recorded for 30 min (b).
Shown are the mean ± SEM,
n = 10. For statistics, see the
‘‘Result’’. Effect of Org25935
(6 mg/kg i.p.) or vehicle on
rearing activity. Results are
displayed as accumulated
counts during the entire 30-min
period (c) and as effect over
time where counts every 5 min
were recorded for 30 min (d).
Shown are the mean ± SEM,
n = 10. For statistics, see the
‘‘Results’’
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treated animals, was observed for Glra2 in nAc p = 0.065,
data not shown). No differences in gene expression
between active group and control group were observed in
any of the brain regions nAc, prefrontal cortex, or dorsal
striatum.
Discussion
This study demonstrates an anti-alcohol-drinking effect of
Org25935 (6 mg/kg) in Wistar rats, even though the drug
initially tended to decrease also water intake, which was
Table 2 Functional operational battery: Score results
Treatment group Total group score Number of scoring rats Total group score Number of scoring rats
Overall status Respiration
AA-Vehicle 14 3 0 0
AA-Org25935 66* 7 11 2
Wis-Vehicle 6 3 0 0
Wis-Org25935 59* 9 0 0
Aggressiveness Body posture
AA-Vehicle 1 1 12 2
AA-Org25935 2 1 67* 7
Wis-Vehicle 5 1 5 5
Wis-Org25935 13 4 55* 9
Muscle tone Catalepsy
AA-Vehicle 0 0 0 0
AA-Org25935 41 4 28 5
Wis-Vehicle 2 1 0 0
Wis-Org25935 9 2 6 2
Righting response Rigidity
AA-Vehicle 0 0 5 2
AA-Org25935 39 4 19 5
Wis-Vehicle 0 0 0 0
Wis-Org25935 3 1 9 3
Vocalisation Piloerection
AA-Vehicle 11 2 0 0
AA-Org25935 0 0 0 0
Wis-Vehicle 14 4 0 0
Wis-Org25935 31* 8 0 0
Effects of acute Org25935 (6 mg/kg i.p.) and vehicle on the neurobehavioral measures in Wistar and AA rats (n = 10). The total group scores
and number of scoring rats per group are presented in Table 2, where * indicates significant p values. * p\ 0.05 For further statistics, see the
‘‘Results’’ section
Fig. 5 Gene expression in Amygdala of genes involved in glycin-
ergic transmission. Fig a displays Glra1 (GlyR subunit a1), Glra2
(GlyR subunit a2), Glra3 (GlyR subunit a3), Glrb (GlyR subunit b),
Slc6a9 (Glycine transporter 1), and Slc6a6 (Taurine transporter). Fig
b displays Slc6a1 (GABA transporter 1), Slc6a11 (GABA transporter
3), and Gphn (gephyrin). Treatment with Org25935 for 19
consecutive days did generally not affect expression of glycinergic
genes. Exceptions were an up-regulation of Slc6a6 (TauT) (a) and a
down-regulation in Slc6a1 (GAT-1) gene expression (b) in
Org25935-treated rats. Shown are the mean ± SEM, n = 6.
**p\ 0.01. Statistics, see ‘‘Results’’. Negative results from the other
brain regions are not presented
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then normalized. This confirms the previously reported
alcohol-sparing effect of Org25935 observed in high
(C60% preference for ethanol) and medium (30–60%
preference for ethanol) alcohol-preferring rats (Molander
et al. 2007) and in rats with relapse-like drinking behavior
(Vengeliene et al. 2010). That another sarcosine-based
non-competitive GlyT-1 inhibitor possesses similar prop-
erties supports a class—rather than a substance-bound
effect (Lifo¨ et al. 2011). Org25935 has demonstrated long-
lasting alcohol intake reducing properties in rodent models
with effects superior to most drug candidates for AUD
(Spanagel and Kiefer 2008). The compound has a good
safety profile and neither animal investigations nor human
studies indicate a positive hedonic profile (Liem-Moole-
naar et al. 2013). However, the attempt to translate these
promising results to AUD patients failed; the proof of
concept trial was aborted before completion due to futility
in the interim analysis (see last section).
To our knowledge, this is the first report of a GlyT-1
inhibitor in AA-rats. The obtained results were unexpected;
Org25935 induced an abrupt CNS depression in AA-rats,
reduced both water and ethanol intake, and caused two
mortalities by respiratory depression on day 2 of treatment.
The symptoms disappeared with dose reduction, but no
specific effect on ethanol consumption was revealed. This
prevented a sound evaluation of the drug’s anti-alcohol-
drinking potential in this strain (see ‘‘Discussion’’, section
five). Distinctions in outcomes across rat strains are a
known phenomenon (Egli 2005). Motor and respiratory
depression for GlyT-1 inhibitors in rodents has been
reported previously, and these effects were attenuated by
the GlyR antagonist strychnine, pointing to involvement of
the GlyR (Perry et al. 2008). That the CNS symptoms were
more pronounced in inbred AA-rats may suggest that the
low dose tolerability has a background in glycinergic
genes. Other possibilities for the differential sensitivity
between strains could be different Org25935 pharmacoki-
netics, or that the larger alcohol intake made AA-rats more
sensitive due to synergistic CNS-depressive effects
between Org25935 and ethanol. Whatever the reason is, the
motor and respiratory depression hampered a meaningful
preclinical evaluation in the AA-rats. Caution must be
taken when utilizing genetic models for generating a cer-
tain phenotype and pharmacogenetics should be considered
in the development and of new drug candidates for AUD.
In this study, Org25935 in the dose 3 mg/kg (raising
extracellular glycine levels by 25%) did not influence
ethanol consumption. Org25935 passes the blood–brain
barrier and systemic administration of 3, 6, or 10 mg/kg
i.p. elevates dialysate glycine levels by 25, 80, and 130%,
respectively (Ge et al. 2001). GlyT-1 blockade at 6 mg/kg
elevated accumbal glycine output by 85% and counteracted
ethanol-induced dopamine release in rat nAc (Lido¨ et al.
2009, 2011). Assuming that the interference with ethanol-
induced dopamine elevation was, at least partly, related to
the alcohol-sparing effect, the dose of 6 mg/kg was
selected for further behavioral assessments. The lack of
effect on alcohol intake with the lower dose is not in
agreement with results from rats with compulsive drinking
following long-term ethanol exposure. In these rats, 3 mg/
kg demonstrated anti-alcohol-drinking effect (Vengeliene
et al. 2010). This could reflect a neurobiological adaptation
in glycinergic mechanisms following chronic ethanol.
The lack of effect of the lower dose of 3 mg/kg (lower
GlyT-1 occupancy) indicates a narrow dose range for
Org25935. Data from non human primates suggest an
inverted-U dose-response curve for cognitive performance
(traditionally thought to be mediated via NMDARs rather
than GlyRs), indicating a complexity in the CSF glycine
level-efficay relationship (Castner et al. 2014). An apparent
bell-shaped dose–efficacy relationship is seen also for other
GlyT-1 compounds and suggests that the optimal phar-
macokinetic level is in a narrow range (Eddins et al. 2014).
GlyT-1 inhibitors have been shown to lose their pro-cog-
nitive effects following GlyT-1 occupancy above 50% due
to NMDAR endocytosis (Harsing et al. 2003, 2006;
Umbricht et al. 2014). Due to the dual receptor binding of
glycine and the lower affinity to the GlyR compared to the
NMDAR, effect responses on alcohol intake may, perhaps,
occur at a distinct dose range as compared to target
responses in schizophrenia. As a comparison, effective
treatment using GlyT-1 inhibition with respect to cognitive
facilitation translates to an approximate 200–250%
increase in striatal glycine (Alberati et al. 2012). GlyT-1
pharmacotherapy may require improved pharmacokinetics
and/or individualized dosing to yield an inhibitory/excita-
tory balance needed for anti-alcohol efficacy.
In the locomotor assessments, Wistar rats demonstrated
higher baseline locomotion compared to AA-rats. Low
baseline motor activity in AA-rats could imply decreased
dopamine function, a phenomenon previously associated
with addiction and which could drive alcohol intake
(Volkow et al. 2007). Yet, neurobiological alterations
underlying alcohol preference in AA-rats are mostly found
in opioid and endocannabinoid mechanisms and not in the
dopamine system (Hyytia 1993; Hyytia et al. 1999; Som-
mer et al. 2006). Acute Org25935 reduced locomotor
activity to the same extent in both strains. As discussed
above, rodents are known to respond to GlyT-1 blockade
with motor and respiratory side-effects which have been
attributed to sustained glycine elevation requiring repeated
dosing (Hashimoto 2011). This may explain why AA tol-
erated the single dose (neurobehavioral study) but not
repeated dosing (consumption study). Kopec et al. reported
hyper-locomotion and compulsive walking after GlyT-1
compounds with high residence time in mice (Kopec et al.
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2010). A speculation explaining the hypo- vs hyper-loco-
motion is that the previously described ataxia (Perry et al.
2008) is expressed to a greater extent in rats, whereas
compulsive walking is expressed more in mice. A stiff and
curved back was observed in rats receiving the GlyT-1
inhibitor, a phenomenon in concordance with the previous
studies and most likely related to the high density of GlyRs
in the rat brain stem (Perry et al. 2008). More AA-rats
responded with rigidity, respiratory depression, reduced
muscle tone, and weakened righting response. Again, this
pattern of CNS depression may indicate pre-existing
abnormalities in glycinergic neurotransmission in AA-rats.
Yet, there is a report of minimal quantitative differences
between mRNA expression of the GlyR subunits in AA and
ANA rats (Jonsson et al. 2009). Accordingly, differences
between AA and ANA rats may lie elsewhere in the neu-
ronal circuitry, in GlyT mechanisms, or in mechanisms
downstream to GlyR activation. That glycine directly
activates the GABAA receptor at high doses could also
account for the CNS depression. Indeed, more pronounced
sedation and muscle relaxation are observed after benzo-
diazepines in AA-rats, compared to ANA rats (Ingman
et al. 2004), i.e., favouring a GABA signaling alteration in
AA-rats. Benzodiazepines are connected to alcohol intake,
where low and high doses may increase and decrease
alcohol consumption, respectively (Soderpalm and Hansen
1998).
Due to the intolerability AA-rats were withdrawn from
further experiments and were not part of the experimental
program when the chronic effects of Org25935 (daily for
19 days) on GABA, GlyT-1, TauT, and GlyR subunit
mRNA expression were examined. We hypothesized that
GlyT-1 blockade would affect gene expression directly
related to inhibitory transmission and result in changes in
GlyR and glycine-related mRNA expression, but the gene
expression study carried out in Wistar rats found that the
rapid tolerance development to the initial CNS depression
in Wistar rats could not be explained by adaptations in the
glycine system. That Org25935 did not evoke changes in
either GlyR subunits or GlyT-1 mRNA expression implies
that the anti-alcohol effect of Org25935 does not involve
general changes in expression of these glycine-related
genes. The robustness of glycinergic gene expression is in
line with results from the previous studies investigating
effects of both selective breeding and alcohol exposure on
the glycinergic system (Jonsson et al. 2009, 2012). In a
compulsive alcohol-drinking model following 1 year of
alcohol exposure, the anti-alcohol properties of Org25935
were manifested for at least 6 weeks during a treatment-
free period (Vengeliene et al. 2010). Chronic alcohol pro-
duced alterations in expression of glycine and glutamate
signaling-related genes, which Org25935 reversed to levels
found in ethanol naı¨ve controls, but no GlyT-genes were
affected by alcohol. Subsequently, Org25935 treatment
reversed many genes affected by ethanol, but not the GlyR
subunit genes further emphasizing the robustness of the
system. It is, however, possible that chronic Org25935
affects the glycinergic and/or the GABAergic system in
other brain regions or via other processes, e.g., protein
synthesis, degradation, or other factors downstream of, or
parallel to, direct GlyR actions. It is noteworthy that the
pattern is distinct from the rapid adaptations known to
occur in the GABAergic system after alcohol exposure,
such as for, e.g., ‘the one glass of wine’ receptor (Olsen
et al. 2007). For review of GABAAR and alcohol effects,
the reader is referred to Krystal et al. (2006).
Other transporters relevant for inhibitory signaling
(presumably affected by Org25935) were also included in
the study, but alterations in transporter gene expression
were only observed in amygdala for both TauT (Slc6a6)
and GAT-1 (Slc6a1). Taurine is structurally similar to
GABA and has been shown to exert some of its effects via
GABAARs, as well as mimicking GABA effects (Olive
2002), i.e., Org25935 could, via changes in taurine levels,
contribute to these alterations. However, taurine levels
appear not to be affected by Org25935 (Ge et al. 2001;
Lido¨ et al. 2009), and expression of Slc6a6 and Slc6a1 was
altered in opposite directions. A limitation in the design is
that amygdala was not divided and analyzed in substruc-
tures, which could have helped explaining the opposing
alternations. That the effects on transporters were observed
exclusively in the amygdala is interesting, since this region
is implicated in different aspects of alcohol-related
behavior and dependence (Roberto et al. 2010, 2012).
Further studies are needed to investigate the potential
involvement of TauT, GAT-1, as well as the amygdala as a
target region in the effects of Org25935.
In sum, the study repeats the robust alcohol reducing
effect of Org25935 inWistar rats, yet only with the high dose
regimen, pointing to a narrow therapeutic range. The previ-
ous preclinical studies justified a Proof of concept study and
Org25935 was rapidly tested in AUD patients, allowing
minimal time to address translational issues (DeBejczy et al.
2014). Org25935 demonstrated no benefit over placebo in
the interim analyses and the trial was stopped due to futility.
However, a number of limitations of the study may have
influenced the outcome, e.g., the lack of an objective marker
for alcohol intake (Walther et al. 2015). Furthermore, the
single-dose designmay have hindered the subjects to achieve
a therapeutic drug level. Observations from our own study
site indicated that patients initially responding with charac-
teristic glycine-related side-effects, like visual disturbances,
reduced their alcohol intake. This may indicate requirement
of a substantial glycine elevation to yield anti-alcohol effi-
cacy. Alternatively, responding individuals may be those
with low baseline glycine levels, in whom there is more
616 H. H. Lido¨ et al.
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scope for elevating receptor occupancy (Heresco-Levy et al.
1999). This could then be a parallel to preclinical findings,
indicating that only a subgroup of rats responds with a
dopamine elevation after glycine elevation with Org25935
(Molander and So¨derpalm 2005b; Lido¨ et al. 2009). That
GlyT-1 inhibitors modulate separate neurotransmitter sys-
tems (glycine, dopamine, and glutamate) further complicates
the picture. In sum, both the present and previous data point
to a heterogeneity of drug action of Org25935 (and similar
compounds). It is possible that therapeutic effects may be
delivered if a responding phenotype can be identified and/or
if acceptable pharmacokinetics can be obtained. In conclu-
sion, despite the lack of a successful clinical outcome, to
date, the unmetmedical need inAUD justifies further studies
of glycinergic compounds and hopefully development of a
new generation of GlyT-1 uptake inhibitors.
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